Ebermin (Ebermin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspOintment for external use.
Composition:100 g of ointment contains:
Active substances:
Epidermal growth factor human recombinant (rchEhF) 0.001 g and Sulfadiazine silver 1.0 g
Auxiliary substances (hydrophilic filler):
Stearic acid 18.00 g, potassium carbonate 0.50 g, methyl parahydroxybenzoate 0.18 g, propyl parahydroxybenzoate 0.02 g, glycerol 5.00 g and purified water c. demand.
Description:White homogeneous mass with a soft consistency of the cream and a weak characteristic odor.
Pharmacotherapeutic group:Means that improve the regeneration of tissues, for topical application.
ATX: & nbsp
  • Other drugs that promote normal scarring
    • Pharmacodynamics:Epidermal growth factor human recombinant (rchEhFR) is a highly purified peptide. It is produced by the strain of the yeast Saccharomyces Cerevisiae, the genome of which is introduced into the genome by the gene of the epidermal growth factor human rchEhF, obtained on the basis of recombinant DNA technology, is identical in mechanism of action to the endogenous epidermal growth factor produced in the body.
    Ebermin, containing as active substances rCHEP and Sulfadiazine silver, has a complex wound healing and bactericidal action. rchEhF stimulates the migration and proliferation of fibroblasts, keratinocytes, endothelial and other cells actively involved in wound healing, promoting epithelialization, scarring and restoration of tissue elasticity.
    Sulfadiazine silver, has a wide range of antimicrobial effects; it is active against Gram-positive and Gram-negative bacteria, Candida fungi and dermatophytes.
    The hydrophilic base of the ointment provides a moderate dehydrating effect, reduces pain, creates and maintains the necessary therapeutic concentrations of the active substances in the lesion site. Ebermin has a cosmetic effect, provides aesthetics of the rumen due to the normalization of the orientation and maturation of collagen fibers, preventing pathological scarring.
    Pharmacokinetics:When applying the drug to intact skin and burn wound surface reabsorption rCHEF from the place of application in the systemic circulation is not observed.
    Indications:The drug is used in adults and children over 1 year to treat superficial and deep skin burns of varying degrees; trophic ulcers (including chronic venous insufficiency, obliterating endarteritis, diabetes, erysipelas); decubitus; long-term non-healing wounds (including wounds of the stump, wounds during autodermoplasty on the sites of lysis and between the surviving autolocuts of the skin,as well as residual wounds at donor sites); violations of the integrity of the skin in injuries, surgical and cosmetological interventions; frostbite; ulcers developing with the administration of cytostatics; treatment and prevention of radiation (radiation) dermatitis (including in the conduct of surface radiotherapy).
    Contraindications:- Hypersensitivity to sulfonamides, silver and other components of the drug.
    - Children under 1 year old.
    The drug should not be used on areas with active tumor lesions and for stimulation of scarring in the areas of surgical excision of tumors.
    Pregnancy and lactation:Ebermin has not been sufficiently studied with regard to the effects on the fetus or infants, so its use is not recommended during pregnancy and during lactation. If a pregnant or breastfeeding woman has a lesion that can be treated with Ebermin, the doctor must determine the risk-benefit ratio and decide on its use.
    Dosing and Administration:Ebermin can be used at all stages of the wound process.
    Preliminary standard surgical treatment of the wound is carried out with the use in case of infectionsolutions of antiseptics. After drying on the wound surface, a layer of ointment is applied about 1-2 mm. When the treatment method is closed, sterile gauze napkins or occlusive film coatings (healing in a moist environment) are placed on top. In a number of cases, for example, with superficial shallow (grade I-II) and partially deep (grade III) burns, it is possible to use an ointment with atraumatic reticular wound covers.
    With a moist method of healing, as well as pronounced exudation, it is recommended to apply the ointment once a day. With moderate or poor exudation, the application of the ointment can be performed once every 2 days. In the case of adhesion of the dressing to the wound and to prevent undesirable drying of the wound surface, it is recommended that the napkin applied over the ointment be moistened with a sterile 0.9% sodium chloride solution or antiseptic solutions. With an open (non-detached) method of treatment, the ointment is applied 1-3 times a day.
    Toilet wounds before re-application of the ointment are carried out using a sterile 0.9% solution of sodium chloride or solutions of antiseptics. The procedure is carried out neatly, avoiding traumatization of the resulting granulation tissue and growing epithelium when removing residual ointments.
    Treatment continues until the epithelization of the wound or its readiness for plastic closure with a skin flap.
    To prevent radiation dermatitis, an ointment with a layer of 1 mm is applied to the irradiated area of ​​the skin without removing it from the application site within 6-8 hours after irradiation. The use of the ointment is continued daily throughout the course of radiotherapy and does not interrupt any of the irradiation procedures in the event of a forced miss.
    Side effects:The drug is well tolerated. In rare cases, it is possible to develop
    - allergic reactions, characteristic of sulfonamide drugs and preparations containing silver;
    - appearance of a burning sensation, pain, contractions and discomfort in the area of ​​application of ointment (usually disappear on their own within 5-10 minutes after the dressing).
    Overdose:There have been no cases of overdose.
    Interaction:Incompatibilities or interactions with other medicines are not noted.
    Special instructions:Use with caution in congenital deficiency of glucose-6-phosphate dehydrogenase, insufficiency of liver and kidney function.
    With an open (non-detached) method of treatment, direct sunlight exposure to the ointment area should be avoided.
    Form release / dosage:Ointment for external use.
    Packaging:For 30 g in sterile white matte color vials of high density polyethylene, with a sterile pressure stopper, with a safety seal.
    For 200 g in sterile white matte color vials of high density polyethylene with a screwed cap of white polypropylene and with a liner of low density polyethylene.
    For 1 bottle in a cardboard box with instructions for use.
    Storage conditions:At a temperature of 15 to 25 ° C in a place protected from light and out of the reach of children.
    Shelf life:2 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:П N012569 / 01
    Date of registration:01.10.2007
    The owner of the registration certificate:Eber Biotech SAEber Biotech SA Cuba
    Manufacturer: & nbsp
    Information update date: & nbsp2016-03-10
    Illustrated instructions
      Instructions
      Up